Relatox Reduces Chronic Migraine Days: New Study Insights
- MigraineMind
- 10 minutes ago
- 1 min read
Research Summary
A recent study published in Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova examined the use of Relatox, a botulinum toxin type A, for chronic migraine treatment. Conducted at a specialized headache center, this open-label study involved 150 patients with an average age of 39. The research showed a significant reduction in migraine days, dropping from 24 to 14 days after 12 weeks of treatment. Remarkably, 61% experienced a ≥30% reduction, 48% saw a ≥50% reduction, and 21% achieved a ≥75% reduction in migraine days. Adverse effects were minimal, occurring in just 3% of patients, confirming Relatox's efficacy and safety.
Study Details
👥 Research Team: Azimova YE et al.
📚 Published In: Zh Nevrol Psikhiatr Im S S Korsakova
📅 Publication Date: 2025
⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.